Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference

作者：Emma Svennberg, José Luís Merino, Jason G. Andrade, Matteo Anselmino, Elena Arbelo, Eric Boersma, Giuseppe Boriani, Günter Breithardt, Mina K. Chung, Janice Y. Chyou, Ariel Cohen, Jan M. Nielsen, Wolfgang Dichtl, Søren Zöga Diederichsen, Dobromir Dobrev, Wolfram Doehner, Elke Dworatzek, Larissa Fabritz, David Filgueiras‐Rama, Claudio Gimpelewicz, Guido Hack, Stéphane Hatem, Jeff S. Healey, Hein Heidbüchel, Ziad Hijazi, Anders G. Holst, Leif Hove‐Madsen, José Jalife, Roderick H. van Leerdam, Dominik Linz, Gregory Y.H. Lip, Steven A. Lubitz, Mirko De Melis, Ralf Meyer, Michał Orczykowski, Abdul Shokor Parwani, Andreu Porta‐Sánchez, Tom De Potter, Ursula Ravens, Michiel Rienstra, Andreas Rillig, Léna Rivard, Douglas S. Scherr, Renate B. Schnabel, Ulrich Schotten, Stefan Simović, Moritz F. Sinner, Christian Sohns, Philipp Sommer, Gerhard Steinbeck, Daniel Steven, Arian Sultan, Götz Thomalla, Tobias Toennis, Stylianos Tzeis, Niels Voigt, Manish Wadhwa, Reza Wakili, Henning Witt, Andreas Goette, Paulus Kirchhof · 发表于：EP Europace · 年份：2025 · DOI：10.1093/europace/euaf318 · 被引用次数：13 · 研究领域：Atrial Fibrillation Management and Outcomes、Cardiac electrophysiology and arrhythmias、Cardiac pacing and defibrillation studies

Atrial fibrillation (AF) is a growing unmet medical need. To reduce its impact on patients' lives, improvements in stroke prevention therapy, treatment of concomitant conditions, and rhythm control therapy are actively developed: Innovations in anti-thrombotic agents, new anti-arrhythmic drugs (AADs), and novel interventional rhythm control therapies emerge alongside AF-reducing effects of general cardiometabolic therapies. Simple risk scores are slowly replaced by personalized AF risk estimation using quantifiable features. These developments were discussed by over 80 experts from academia and industry during the 10th Atrial Fibrillation NETwork /European Heart Rhythm Association consensus conference from 5 to 7 May 2025. The emerging consensus, described here, is multi-domain therapy combining stroke prevention, rhythm control, and therapy of concomitant cardiovascular conditions. This combines anti-coagulants, AADs, and AF ablation with old and new cardiometabolic drugs that can reduce AF risk, AF burden, and AF-related complications at scale. The paper furthermore describes quantitative traits that may enable a shift towards risk-driven therapy based on AF phenotypes. These can enable adjusted therapy strategies that are safe, accessible, and patient-centred. Applying modern data science and artificial intelligence methods to quantitative phenotypic and genetic features can further improve risk estimation and personalized therapy selection. At the same time, translational...